Drug Profile
Research programme: rho kinase inhibitors - Charles River Laboratories
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Charles River Laboratories
- Class Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease